PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Announces that its founded firm Entity Vedanta Biosciences Inc launches a new manufacturing facility. The facility will "provide clinical and commercial supply of oral therapies" for people infected with a diarrhoea-causing bacteria, firm says.
It is "designed to manufacture clinical and commercial supply for its therapeutic portfolio, including for the planned phase 3 study and potential commercial launch of its lead candidate, VE303, in clostridioides difficile infection", it says, referring to a bacteria that can cause diarrhoea. It contributes to around 45,000 deaths in the US every year, the company says.
The facility "builds on the company's existing manufacturing capabilities and can produce multiple drug candidates in a manner compliant with global regulatory standards, supporting Vedanta's clinical expansion," PureTech continues.
Current stock price: 171.80 pence, up 0.7% on Tuesday
12-month change: down 50%
By Tom Budszus; tombudszus@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
PureTech (PRTC)